PISCATAWAY, N.J., April 14, 2026 /PRNewswire/ -- GenScript Biotech Corporation today announced its 2025 Environmental, Social, and Governance (ESG) Report, positioning the company at the forefront of ...

SAN FRANCISCO--(BUSINESS WIRE)--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and GenScript Biotech Corporation ...

NANJING, China, Jan. 4, 2024 /PRNewswire/ -- GenScript Biotech, a global leader in life science research and manufacturing services, along with its subsidiaries GenScript ProBio and Legend Biotech, ...

Recent price moves and business snapshot Genscript Biotech (SEHK:1548) has seen the stock slip about 0.5% on the day and roughly 5.6% over the past week, while posting a gain of around 13% over the ...

May 31 (Reuters) - The U.S. House of Representatives committee on China has asked the FBI and the intelligence community for a briefing on GenScript Biotechnology Co (1548.HK), opens new tab and three ...

Genscript Biotech (HK:1548) has released an update. Genscript Biotech Corporation announced the unaudited financial results for the third quarter of 2024 for its associate, Legend Biotech Corporation, ...

In the rapidly evolving world of cancer treatments, CAR-T cell therapy stands out for its effectiveness tackling hematologic tumors. Booming demand for such therapies powered Legend Biotech Corp. LEGN ...

(Reuters) -The U.S. House of Representatives committee on China on Tuesday sent a letter to the directors of the FBI and national intelligence, renewing its concerns about GenScript Biotechnology's ...

Good day and thank you for standing by. Welcome to Genscript Biotech 2025 Interim Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, ...

Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its 48% holding ...

Earnings call GenScript delivered 61.4% year-over-year revenue growth to $959.5M in 2025, with adjusted net profit surging 285% to $230.3M and all core segments outperforming. Management issued robust ...